Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals: a net loss increase and revenue decline are offset by positive gross margin improvements and a disciplined share repurchase plan. The Q&A highlights cautious optimism in Pennsylvania and Maryland but challenges in New Jersey and Ohio. No significant new partnerships or guidance changes were announced. The lack of clarity on M&A plans and market dynamics further tempers sentiment. Overall, the mixed financial results and cautious outlook suggest a neutral stock price reaction.
Revenue (Q4 2025) $66.1 million, a 1.6% sequential increase from $65.1 million in Q3 2025. The increase was driven by retail revenue growth, while wholesale revenue remained stable to modestly higher.
Full Year Revenue (2025) $260.6 million, a decrease from $268.1 million in 2024. The decline was primarily due to pricing compression in New Jersey, partially offset by growth in Pennsylvania and Maryland.
Gross Margin (Full Year 2025) 52.3%, up from 50.7% in 2024. The improvement was due to better vertical integration efficiencies and disciplined cost management.
Gross Margin (Q4 2025) 52.1%, stable quarter-over-quarter. Pricing pressure in New Jersey was offset by strong performance in Maryland.
Adjusted EBITDA (Full Year 2025) $67.8 million (26% margin), down from $70.2 million (26.2% margin) in 2024. The decline reflects revenue headwinds.
Adjusted EBITDA (Q4 2025) $16.7 million (25.2% margin), slightly down from $17 million (26.1% margin) in Q3 2025. The decline was due to gross margin compression in New Jersey and targeted wholesale investments.
Operating Cash Flow (Full Year 2025) $33.9 million, down from $46.2 million in 2024. The decline was due to one-time tax refunds in the prior year.
Operating Cash Flow (Q4 2025) $8.3 million, marking the 14th consecutive quarter of positive operating cash flow.
Free Cash Flow (Full Year 2025) $25.3 million, marking the 10th consecutive quarter of positive free cash flow.
Free Cash Flow (Q4 2025) $6.6 million.
Net Loss (Full Year 2025) $24.5 million, compared to $11.5 million in 2024. The increase was driven by other non-cash operating items.
Net Loss (Q4 2025) $0.5 million, a significant improvement from $9.9 million in Q3 2025.
Cash and Cash Equivalents (End of Q4 2025) $37.4 million, up from $36.6 million at the end of Q3 2025.
New product launches in Pennsylvania: Increased capacity at cultivation facility to support new product launches.
Legend vape and pre-rolls: Legend vape sales grew 12% quarter-over-quarter, and Legend pre-rolls delivered their highest sales quarter to date, growing approximately 85% sequentially.
Valhalla Edibles: Valhalla gained category share every quarter in 2025.
Market expansion in New Jersey: Completed Union Chill transaction, expanding retail footprint to 4 dispensaries with plans to grow to 10 dispensaries.
Entry into Ohio: Acquired assets of Ratio Cannabis, fully integrated into operations.
Exit from Michigan: Completed majority of asset sales, reducing liabilities and debt exposure.
Operational cash flow: Generated $33.9 million in operating cash flow for the full year, marking 14 consecutive quarters of positive operating cash flow.
Free cash flow: Achieved $25.3 million in free cash flow for the full year, marking 10 consecutive quarters of positive free cash flow.
Gross margins: Gross margins for the full year were over 52%, with Maryland nearing 60% in Q4.
M&A strategy: Focused on disciplined acquisitions, particularly distressed assets in core markets like New Jersey and Pennsylvania.
Debt refinancing: Completed $79 million non-dilutive debt financing, extending maturities to 2028 and reducing near-term refinancing risk.
Regulatory reform: Monitoring federal rescheduling of marijuana, which could provide upside to operations.
Pricing Compression in New Jersey: Wholesale revenue decreased quarter-over-quarter due to price compression, and gross margins in the state declined slightly due to the competitive pricing environment.
Regulatory Uncertainty: The formal rescheduling process for marijuana remains subject to agency rulemaking and implementation timelines, creating uncertainty around regulatory reform.
Exit from Michigan: The company is in the final stages of exiting Michigan, which involves negotiating down liabilities and exposure. This process could pose financial and operational challenges.
Debt Management: While the company has extended the majority of its debt maturities to 2028, it still carries significant debt, which could impact financial flexibility.
Social Equity License Rollout in Maryland: The impact of Maryland's social equity license rollout is being evaluated, which could affect market dynamics and competition.
Retail and Wholesale Revenue Variability: Retail revenue in Maryland declined quarter-over-quarter, and wholesale revenue in New Jersey decreased due to pricing pressures, indicating variability in revenue streams.
Net Loss Increase: Net loss from continuing operations for the full year 2025 increased to $24.5 million from $11.5 million in 2024, driven by noncash operating items.
Revenue and Gross Margins Outlook for Q1 2026: The company expects revenue and gross margins for Q1 2026 to be similar to the results reported for Q4 2025.
Retail Expansion in New Jersey: The company plans to expand its retail presence in New Jersey to the current maximum of 10 dispensaries to strengthen its leadership position in the state.
Cultivation Expansion in Pennsylvania: The company has reactivated 6 additional cultivation rooms in Pennsylvania, increasing total flower output by roughly 50%. The first harvest is expected in April 2026, with products available for sale in June 2026. This expansion leverages existing infrastructure and requires no incremental CapEx.
M&A Strategy and Financial Flexibility: The company is evaluating attractive distressed assets, particularly in New Jersey and Pennsylvania, and has an additional uncommitted term loan of up to $35 million to support future strategic M&A.
Ohio Market Strategy: The company aims to assemble a leading retail footprint in Ohio through disciplined acquisitions while leveraging its infrastructure to drive profitability.
Regulatory Reform Impact: The company is monitoring federal and state regulatory developments, including the White House's executive order to expedite the rescheduling process of marijuana. Any successful reform is considered an upside to the company's plan.
Share Repurchase Program: In 2025, the company renewed or replenished its normal course issuer bid, authorizing up to an additional $10 million in repurchases through August 2026. During 2025, the company repurchased over 1.1 million shares at a weighted average price of USD 0.44 per share. The company plans to continue executing on the buyback in a disciplined manner, while balancing growth investments, capital expenditures, and selective M&A.
The earnings call reveals mixed signals: a net loss increase and revenue decline are offset by positive gross margin improvements and a disciplined share repurchase plan. The Q&A highlights cautious optimism in Pennsylvania and Maryland but challenges in New Jersey and Ohio. No significant new partnerships or guidance changes were announced. The lack of clarity on M&A plans and market dynamics further tempers sentiment. Overall, the mixed financial results and cautious outlook suggest a neutral stock price reaction.
The earnings call summary and Q&A indicate a positive outlook. Despite flat revenue growth, strong EBITDA and strategic initiatives like Project Aurora and Hinge's international expansion are promising. The company's focus on AI innovations, improved user engagement, and a balanced investment strategy in product improvements and shareholder returns further support a positive sentiment. The Q&A reveals management's confidence in overcoming challenges, and the optimistic guidance for Q4 2025 suggests potential stock price gains.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.